Global Prevalence of Dual HSV-1 and HSV-2 Infection
The available evidence does not provide a specific global percentage for co-infection with both HSV-1 and HSV-2, but data suggests approximately 4% of the population aged 15-49 years has dual infection, based on limited regional studies.
What the Evidence Shows
Population-Based Data on Co-Infection
In Japan, approximately 4% of adults (2.3% of men and 5.0% of women) were co-infected with both HSV-1 and HSV-2 in a population-based cohort study 1
This represents the most specific data available on dual infection rates from a well-characterized population sample 1
Individual Virus Prevalence Globally
To understand the context of co-infection, the individual prevalence rates are:
HSV-2 global prevalence: 13.2-13.3% of people aged 15-49 years (approximately 491.5-519.5 million people) 2, 3
HSV-1 global prevalence: 66.6-67% of people aged 0-49 years (approximately 3.7 billion people with any HSV-1 infection) 2, 4
Genital HSV-1 prevalence: 10.2% of people aged 15-49 years (approximately 376.2 million people) 3
Evidence of Protective Cross-Immunity
Important caveat: Prior HSV-1 infection appears to provide partial protection against subsequent HSV-2 acquisition 5
The odds ratio for HSV-2 infection among HSV-1 seropositive individuals was 0.71 for men and 0.81 for women in U.S. data, indicating 19-29% reduced odds of HSV-2 infection when already infected with HSV-1 5
In Japan, HSV-2 prevalence among HSV-1 infected individuals was lower than among uninfected individuals for both sexes 1
This cross-protection likely explains why co-infection rates are lower than would be expected from independent infection probabilities 5, 1
Clinical Implications
Co-infection occurs but is relatively uncommon compared to single-virus infection, likely due to immunological cross-protection 5, 1
When HSV-1 antibodies are present first (typically from childhood oral infection), subsequent genital HSV-2 infection tends to be less severe 6
The global burden is dominated by single infections: billions with HSV-1 (mostly oral) and hundreds of millions with HSV-2 (predominantly genital) 2, 3
Limitations of Available Data
The evidence base for precise co-infection rates is limited - most epidemiological studies report HSV-1 and HSV-2 prevalence separately rather than specifically quantifying dual infection 2, 3, 4. The 4% estimate from Japan may not be generalizable globally, as HSV prevalence varies substantially by region, with higher rates in Africa and lower rates in developed Western countries 7, 2.